Literature DB >> 17451219

Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.

Aspasia S Soultati1, Spyridon P Dourakis, Alexandra Alexopoulou, Melanie Deutsch, Athanasios J Archimandritis.   

Abstract

Classical interferon-alpha has been shown to be correlated with the development of a variety of autoimmune disorders. A 38 year-old female patient developed simultaneously diabetic ketoacidosis and hyperthyroidism 5 mo following initiation of treatment with pegylated interferon-alpha and ribavirin for chronic hepatitis C. High titers of glutamic acid decarboxylase, antinuclear and thyroid (thyroid peroxidase and thyroglobulin) antibodies were detected. Antiviral treatment was withdrawn and the patient was treated with insulin for insulin-dependent diabetes mellitus and propranolol for hyperthyroidism. Twelve months after cessation of pegylated interferon-alpha therapy the patient was euthyroid without any medication but remained insulin-dependent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451219      PMCID: PMC4147013          DOI: 10.3748/wjg.v13.i8.1292

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis.

Authors:  P Fabris; C Betterle; N A Greggio; R Zanchetta; E Bosi; M R Biasin; F de Lalla
Journal:  J Hepatol       Date:  1998-03       Impact factor: 25.083

2.  Interferon-alpha and IDDM: comment.

Authors:  A K Foulis
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

3.  Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy.

Authors:  M Deutsch; S Dourakis; E K Manesis; A Gioustozi; G Hess; A Horsch; S Hadziyannis
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

4.  Side effects of high-dose interferon therapy for chronic hepatitis C.

Authors:  T Okanoue; S Sakamoto; Y Itoh; M Minami; K Yasui; M Sakamoto; K Nishioji; T Katagishi; Y Nakagawa; H Tada; Y Sawa; M Mizuno; K Kagawa; K Kashima
Journal:  J Hepatol       Date:  1996-09       Impact factor: 25.083

Review 5.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

6.  Interferon induces insulin resistance in patients with chronic active hepatitis C.

Authors:  E Imano; T Kanda; Y Ishigami; M Kubota; M Ikeda; M Matsuhisa; R Kawamori; Y Yamasaki
Journal:  J Hepatol       Date:  1998-02       Impact factor: 25.083

7.  A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

Authors:  G Fattovich; G Giustina; S Favarato; A Ruol
Journal:  J Hepatol       Date:  1996-01       Impact factor: 25.083

Review 8.  Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity.

Authors:  D Devendra; G S Eisenbarth
Journal:  Clin Immunol       Date:  2004-06       Impact factor: 3.969

9.  Effect of interferon on glucose tolerance and insulin sensitivity.

Authors:  V A Koivisto; R Pelkonen; K Cantell
Journal:  Diabetes       Date:  1989-05       Impact factor: 9.461

Review 10.  [Glucose intolerance during interferon therapy in patients with chronic hepatitis type C].

Authors:  Y Ishigami; T Kanda; M Wada; Y Shimizu
Journal:  Nihon Rinsho       Date:  1994-07
View more
  6 in total

Review 1.  Interferon therapy in hepatitis C leading to chronic type 1 diabetes.

Authors:  Taiba Zornitzki; Stephen Malnick; Lyudmila Lysyy; Hilla Knobler
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

2.  Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B.

Authors:  Yuan-Yuan Lv; Bing-Yin Shi; Hui Guo
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

3.  Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review.

Authors:  Reiko Oka; Naoki Hiroi; Rika Shigemitsu; Mariko Sue; Yasuo Oshima; Mayumi Yoshida-Hiroi
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2011-08-23

4.  Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto's thyroiditis: a case report.

Authors:  Maria Xenou; Ioannis Zoupas; Dimitrios Lygnos; Evangelos Fousteris
Journal:  J Med Case Rep       Date:  2022-08-03

5.  A systematic review and meta-analysis of endocrine-related adverse events associated with interferon.

Authors:  Linghuan Wang; Binqi Li; He Zhao; Peixin Wu; Qingzhen Wu; Kang Chen; Yiming Mu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

6.  Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations.

Authors:  Clio P Mavragani; Timothy B Niewold; Antonis Chatzigeorgiou; Stamatina Danielides; Dimitrios Thomas; Kyriakos A Kirou; Elli Kamper; Grigorios Kaltsas; Mary K Crow
Journal:  Front Immunol       Date:  2013-08-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.